These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1892365)
21. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients. Kostić VS; Covicković-Sternić N Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052 [TBL] [Abstract][Full Text] [Related]
23. [Long-term problems of levodopa therapy in Parkinson disease]. Albani C; Asper R; Baumgartner G Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050 [TBL] [Abstract][Full Text] [Related]
24. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Djaldetti R; Melamed E Ann Neurol; 1996 Mar; 39(3):400-4. PubMed ID: 8602763 [TBL] [Abstract][Full Text] [Related]
25. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601 [TBL] [Abstract][Full Text] [Related]
26. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol; 1999; 22(4):220-5. PubMed ID: 10442252 [TBL] [Abstract][Full Text] [Related]
27. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa. Okereke CS J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867 [TBL] [Abstract][Full Text] [Related]
28. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Sage JI; Schuh L; Heikkila RE; Duvoisin RC Clin Neuropharmacol; 1988 Feb; 11(1):36-44. PubMed ID: 3349496 [TBL] [Abstract][Full Text] [Related]
30. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease]. Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460 [TBL] [Abstract][Full Text] [Related]
31. Complications and limitations of drug therapy for Parkinson's disease. Jankovic J Neurology; 2000; 55(12 Suppl 6):S2-6. PubMed ID: 11188970 [TBL] [Abstract][Full Text] [Related]
32. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease]. Rondot P; Ziegler M; Aymard N; Holzer J Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265 [TBL] [Abstract][Full Text] [Related]
33. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Arabia G; Zappia M; Bosco D; Crescibene L; Bagalà A; Bastone L; Caracciolo M; Scornaienghi M; Quattrone A Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340 [TBL] [Abstract][Full Text] [Related]
34. [Motor complications in patients with Parkinson disease treated with levodopa]. Luquin MR; Obeso JA; Martínez-Lage JM Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806 [TBL] [Abstract][Full Text] [Related]
35. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222 [TBL] [Abstract][Full Text] [Related]
36. Effects of slowed gastrointestinal motility on levodopa pharmacokinetics. Fernández N; García JJ; Diez MJ; Sahagún AM; González A; Díez R; Sierra M Auton Neurosci; 2010 Aug; 156(1-2):67-72. PubMed ID: 20434962 [TBL] [Abstract][Full Text] [Related]
37. [Levodopa loading test as an early marker of Parkinson's disease]. Hatori K; Kondo T; Mizuno Y Nihon Rinsho; 1997 Jan; 55(1):207-12. PubMed ID: 9014451 [TBL] [Abstract][Full Text] [Related]